Literature DB >> 34545414

Synthesis, characterization and antitumor mechanism investigation of ruthenium(II) polypyridyl complexes with artesunate moiety.

Bi-Chun Chen1, Jun-Jian Lu1, Ning Jiang1, Xiu-Rong Ma1, Rong-Tao Li1, Rui-Rong Ye2.   

Abstract

Six artesunate (ART) conjugated ruthenium(II) complexes (Ru(II)-ART conjugates) with the formula [Ru(N^N)2bpy(4-CH3-4'-CH2OART)](PF6)2 (Ru-ART-1-3) and [Ru(N^N)2bpy(4-CH2OART-4'-CH2OART)](PF6)2 (Ru-ART-4-6) (N^N = 2,2'-bipyridine (bpy, in Ru-ART-1 and Ru-ART-4), 1,10-phenanthroline (phen, in Ru-ART-2 and Ru-ART-5) and 4,7-diphenyl-1,10-phenanthroline (DIP, in Ru-ART-3 and Ru-ART-6)), were synthesized and characterized. Among them, Ru-ART-1-3 and Ru-ART-4-6 carry one and two ART moieties, respectively. Ru-ART-3 and Ru-ART-6 exhibit better cytotoxicity among six Ru(II)-ART conjugates. These two complexes can be effectively taken up by human cervical carcinoma (HeLa) cells. In addition, they selectively kill cancer cell lines while mildly affect normal cells. Mechanism studies have shown that HeLa cells treated with Ru-ART-3 and Ru-ART-6 show typical apoptotic characteristics (morphology changes, mitochondrial dysfunction, caspase cascade, etc.). On the other hand, the up regulation of Beclin-1 and conversion of LC3-I to LC3-II note the appearance of autophagy. As a result, Ru-ART-3 and Ru-ART-6 induce autophagy-dependent cell apoptosis via mitochondrial dysfunction and reactive oxygen species (ROS) accumulation. In this work, six artesunate (ART) conjugated ruthenium(II) complexes (Ru(II)-ART conjugates) have been synthesized and characterized. Among them, Ru-ART-3 and Ru-ART-6 exhibit better cytotoxicity. Mechanism studies have shown that HeLa cells treated with Ru-ART-3 and Ru-ART-6 show typical apoptotic characteristics (morphology changes, mitochondrial dysfunction, caspase cascade, etc.). On the other hand, the up regulation of Beclin-1 and conversion of LC3-I to LC3-II note the appearance of autophagy.
© 2021. Society for Biological Inorganic Chemistry (SBIC).

Entities:  

Keywords:  Anticancer activity; Apoptosis; Artesunate; Autophagy; Ruthenium(II) complexes

Mesh:

Substances:

Year:  2021        PMID: 34545414     DOI: 10.1007/s00775-021-01901-8

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  47 in total

Review 1.  Ruthenium anticancer drugs.

Authors:  Enzo Alessio; Giovanni Mestroni; Alberta Bergamo; Gianni Sava
Journal:  Met Ions Biol Syst       Date:  2004

2.  First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro.

Authors:  Debora Wernitznig; Konstantinos Kiakos; Giorgia Del Favero; Nathalie Harrer; Herwig Machat; Annika Osswald; Michael A Jakupec; Andreas Wernitznig; Wolfgang Sommergruber; Bernhard K Keppler
Journal:  Metallomics       Date:  2019-06-19       Impact factor: 4.526

Review 3.  Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?

Authors:  Sreekanth Thota; Daniel A Rodrigues; Debbie C Crans; Eliezer J Barreiro
Journal:  J Med Chem       Date:  2018-02-26       Impact factor: 7.446

4.  Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids.

Authors:  Debora Wernitznig; Samuel M Meier-Menches; Klaudia Cseh; Sarah Theiner; Dominik Wenisch; Andreas Schweikert; Michael A Jakupec; Gunda Koellensperger; Andreas Wernitznig; Wolfgang Sommergruber; Bernhard K Keppler
Journal:  Metallomics       Date:  2020-12-23       Impact factor: 4.526

5.  In vitro cytotoxicity and in vivo zebrafish toxicity evaluation of Ru(ii)/2-mercaptopyrimidine complexes.

Authors:  Vivianne S Velozo-Sá; Luciano R Pereira; Aliny P Lima; Francyelli Mello-Andrade; Manuela R M Rezende; Rebeca M Goveia; Wanessa C Pires; Monize M Silva; Katia M Oliveira; Antonio G Ferreira; Javier Ellena; Victor M Deflon; Cesar Koppe Grisolia; Alzir A Batista; Elisângela P Silveira-Lacerda
Journal:  Dalton Trans       Date:  2019-05-07       Impact factor: 4.390

Review 6.  Ruthenium antimetastatic agents.

Authors:  Enzo Alessio; Giovanni Mestroni; Alberta Bergamo; Gianni Sava
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

7.  Coordination-driven self-assembly of ruthenium(ii) architectures: synthesis, characterization and cytotoxicity studies.

Authors:  Aderonke Ajibola Adeyemo; Abhijith Shettar; Imtiyaz Ahmad Bhat; Paturu Kondaiah; Partha Sarathi Mukherjee
Journal:  Dalton Trans       Date:  2018-06-25       Impact factor: 4.390

8.  Ruthenium polypyridyl complexes as inducer of ROS-mediated apoptosis in cancer cells by targeting thioredoxin reductase.

Authors:  Zuandi Luo; Lianling Yu; Fang Yang; Zhennan Zhao; Bo Yu; Haoqiang Lai; Ka-Hing Wong; Sai-Ming Ngai; Wenjie Zheng; Tianfeng Chen
Journal:  Metallomics       Date:  2014-08       Impact factor: 4.526

9.  Anti-metastasis and anti-proliferation effect of mitochondria-accumulating ruthenium(II) complexes via redox homeostasis disturbance and energy depletion.

Authors:  Lina Xie; Lili Wang; Ruilin Guan; Liangnian Ji; Hui Chao
Journal:  J Inorg Biochem       Date:  2021-02-03       Impact factor: 4.155

10.  Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.

Authors:  Lea S Flocke; Robert Trondl; Michael A Jakupec; Bernhard K Keppler
Journal:  Invest New Drugs       Date:  2016-03-18       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.